No Effect of Cloricromen on Some Coagulation Parameters in Patients with Ischaemic Cerebrovascular Disease

Abstract

Cloricromen is a new drug that inhibits platelet aggregation in man and in experimental thrombosis. Twenty patients with a history of atherothrombotic stroke received cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system. A statistically significant decrease in the prothrombin time (P < 0.01) was found only after 30 days of therapy. This decrease was transient and disappeared 15 days after the end of treatment. No statistically significant changes in plasma fibrinogen levels, antithrombin III, partial thromboplastin time, or platelet count were observed compared with baseline values. No side-effects were reported. This study did not reveal an effect of cloricromen on coagulative variables in patients with cerebrovascular occlusive disease.

A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat

“…The results of the present study were roughly in accordance with a small clinical study where 20 patients received a dose of 100 mg cloricromene orally twice daily over 30 days (Orefice et al, 1994). These authors reported only a small but significant transient decrease of prothrombin time after one Table 1 Evolution of body weight, colon variables, blood coagulation parameters, and tissue MIP-2 concentrations in controls, vehicletreated colitis, and cloricromene-treated (10 mg/kg/b.i.d.)…”

Abnormal Changes in Some Haemostatic Parameters in First-ever Stroke Patients in Port Harcourt, Nigeria: A Preliminary Findings

“…They attributed the decrease concentration to its consumption during fibrinolysis; while, Orefice et al [27] observed no statistically significant difference between the two groups.…”

Synthetic and natural coumarins as potent anticonvulsant agents: A review with structure–activity relationship

“…Some of the coumarin‐based drugs are available in the markets to quote a few, hymecromone ( 4 , antispasmodic and choleretic), 55 warfarin ( 5 , anticoagulant, or blood thinner), 56 batoprazine ( 6 , anti‐aggression agent), 57 difenacoum ( 7 , anticoagulants and a pesticide), 58 ensaculin ( 8 , treatment for dementia, NMDA antagonist and a 5HT 1A agonist), 59 tecarfarin ( 9 , anticoagulant), 60 auraptene ( 10 , an antineoplastic agent, an apoptosis inducer, a dopaminergic agent, a neuroprotective agent, an antihypertensive agent, a gamma‐secretase modulator), 61 acenocoumarol ( 11 , anticoagulant, prevents the formation of harmful blood), 62 carbochromen ( 12 , coronary vasodilator), 63 coumaphos ( 13 , insecticide and pesticide), 64 phenprocoumon ( 14 , anticoagulant), 65 novobiocin ( 15 , antimicrobials), 66 brodifacoum ( 16 , anticoagulant and pecticide), 67 dicoumarol/dicumarol ( 17 , anticoagulant, inhibitor of reductases), 68 cloricromen ( 18 , platelet aggregation inhibitor) 69 and scopoletin ( 19 , antifunagal) 70 (Figure 2).…”